Skip to contentSkip to filters

We use cookies for analytics.

Grant, Call number PAR-25-297

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

National Institutes of Health

Related content

About

A cooperative agreement supports preclinical and early clinical development of drug candidates aimed at preventing Alzheimer’s disease, slowing its progression or treating cognitive and behavioral symptoms. Eligible activities include pharmacology, efficacy studies, target-engagement biomarkers and early clinical development.

Topics

Eligibility

Covers: Supports preclinical and early clinical development, including phase I work.

The lead applicant must be an eligible US organization. Eligible non-US components of US organizations may participate.

simpler.grants.govgrants.nih.gov

Eligible organizations include universities, nonprofit research organizations and other categories specified in the announcement. The lead applicant must be an eligible US organization. Eligible non-US components of US organizations may participate.

Source: simpler.grants.gov